Regulatory Affairs
Anchor Your Product’s Evidence in Regulatory Reality.
Anchor Your Product’s Evidence in Regulatory Reality.
Regulatory Affairs anchors the product story in evidence.
This is where we define what must be true, not what we hope, but what can be defended under agency scrutiny.
From early scientific advice through global submissions, we ensure the evidence base, claims architecture, and development strategy align before pressure is applied. When this foundation is sound, every downstream function inherits credibility.
Our role is not simply to prepare documentation. It is to ensure the regulatory position strengthens – rather than constrains – access, commercial, and capital strategy.
Our Services Include:
- Scientific advice briefing packages (EMA/FDA)
- Orphan Drug Designation (ODD) applications
- Regulatory roadmaps and pathway strategy (including PRIME, Fast Track, Breakthrough)
- Modules 2, 4, and 5 submission content, including summaries, study reports, and integrated documents
- Drafting, cross-document consistency, and version control using structured, tech-enabled workflows
- Global dossier tracking and lifecycle support
- CMC-related regulatory documentation and submission coordination (in collaboration with specialist CMC teams)
These services are delivered within a coherent regulatory architecture, ensuring submissions are not just compliant but strategically aligned with long-term product positioning.
Case Studies
Biotech | Switzerland – Regulatory
Writing & Dual-Agency Submission Support
Challenge:
A rare-disease programme required parallel EMA and FDA filings under compressed timelines, with fragmented internal inputs and inconsistent narrative positioning across workstreams.
Solution: We embedded senior regulatory leadership to define the defensible evidence position first, aligning clinical summaries, CMC documentation, and cross-functional inputs around a coherent regulatory thesis before submission drafting began.
Impact:
Submission-ready dossiers delivered on time, with reduced review cycle friction and clear alignment between agency expectations and internal strategy.
